The long term antibody persistence study of GSK Biologicals’ meningococcal vaccine GSK 134612 administered as 1 or 2 doses to healthy toddlers at 9-12 months of age and as a booster dose at 5 years post-primary vaccination
Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine
Infections, Meningococcal
Phase 2
This is a follow-up study to 109375. An annotated case report form is not available for this study. A blank case report form will be provided.
February 2015